Aquatic Capital Management LLC Purchases New Position in Viking Therapeutics, Inc. (NASDAQ:VKTX)

Aquatic Capital Management LLC purchased a new stake in Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 209,134 shares of the biotechnology company's stock, valued at approximately $8,416,000. Aquatic Capital Management LLC owned approximately 0.19% of Viking Therapeutics as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Blue Trust Inc. lifted its position in Viking Therapeutics by 75.9% during the 4th quarter. Blue Trust Inc. now owns 716 shares of the biotechnology company's stock worth $29,000 after buying an additional 309 shares in the last quarter. YANKCOM Partnership acquired a new position in shares of Viking Therapeutics during the fourth quarter worth approximately $33,000. FIL Ltd grew its stake in shares of Viking Therapeutics by 116.8% during the fourth quarter. FIL Ltd now owns 1,203 shares of the biotechnology company's stock valued at $48,000 after purchasing an additional 648 shares during the last quarter. CIBC Private Wealth Group LLC increased its holdings in shares of Viking Therapeutics by 170.2% in the fourth quarter. CIBC Private Wealth Group LLC now owns 1,351 shares of the biotechnology company's stock valued at $55,000 after purchasing an additional 851 shares in the last quarter. Finally, S.A. Mason LLC raised its position in Viking Therapeutics by 20.0% in the 4th quarter. S.A. Mason LLC now owns 1,800 shares of the biotechnology company's stock worth $72,000 after purchasing an additional 300 shares during the last quarter. Institutional investors and hedge funds own 76.03% of the company's stock.

Analyst Ratings Changes

A number of research analysts have commented on VKTX shares. Citigroup started coverage on Viking Therapeutics in a research report on Friday, February 7th. They issued a "neutral" rating and a $38.00 price objective on the stock. HC Wainwright reiterated a "buy" rating and issued a $102.00 price objective on shares of Viking Therapeutics in a research report on Thursday. Maxim Group dropped their price objective on Viking Therapeutics from $120.00 to $70.00 and set a "buy" rating for the company in a report on Friday, February 7th. Piper Sandler reduced their target price on shares of Viking Therapeutics from $74.00 to $71.00 and set an "overweight" rating on the stock in a research note on Thursday, February 6th. Finally, Morgan Stanley dropped their price target on shares of Viking Therapeutics from $105.00 to $102.00 and set an "overweight" rating for the company in a research note on Thursday. One investment analyst has rated the stock with a sell rating, two have given a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $89.50.

Insiders Place Their Bets

In other news, Director Sarah Kathryn Rouan acquired 1,240 shares of the firm's stock in a transaction that occurred on Monday, March 31st. The stock was acquired at an average cost of $24.15 per share, for a total transaction of $29,946.00. Following the completion of the acquisition, the director now owns 1,240 shares in the company, valued at $29,946. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 4.10% of the company's stock.

Viking Therapeutics Trading Down 2.6 %

Shares of Viking Therapeutics stock opened at $24.99 on Friday. Viking Therapeutics, Inc. has a 12 month low of $18.92 and a 12 month high of $81.86. The stock's fifty day simple moving average is $26.47 and its 200 day simple moving average is $40.49. The company has a market capitalization of $2.81 billion, a PE ratio of -24.99 and a beta of 0.84.

Viking Therapeutics (NASDAQ:VKTX - Get Free Report) last announced its earnings results on Wednesday, April 23rd. The biotechnology company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.07). During the same period in the previous year, the business posted ($0.26) EPS. Analysts predict that Viking Therapeutics, Inc. will post -1.56 EPS for the current fiscal year.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.

Want to see what other hedge funds are holding VKTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.